ALB and cancer: Taken together, [64Cu]Cu-NOTA-TP-c(RGDfK) emerges as a promising CRT candidate, integrating selective αvβ3 integrin targeting, albumin-mediated binding enhancement, and the radiotherapeutic properties of 64Cu into a single agent—offering a rational strategy to improve both cancer cell specificity and cytoxicity.